Atrial Fibrillation

• 

  Subject Areas on Research

  • 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. 
  • 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. 
  • 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 
  • 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. 
  • 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. 
  • 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. 
  • A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation. 
  • A Cluster Analysis of the Japanese Multicenter Outpatient Registry of Patients With Atrial Fibrillation. 
  • A Simple Score That Predicts Paroxysmal Atrial Fibrillation on Outpatient Cardiac Monitoring after Embolic Stroke of Unknown Source. 
  • A Supervised Approach to Robust Photoplethysmography Quality Assessment. 
  • A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. 
  • A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale. 
  • A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. 
  • A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation. 
  • A membrane model of electrically remodelled atrial myocardium derived from in vivo measurements. 
  • A multi-population phenome-wide association study of genetically-predicted height in the Million Veteran Program. 
  • A multicenter risk index for atrial fibrillation after cardiac surgery. 
  • A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. 
  • A new era of anticoagulation treatment: optimizing outcomes for atrial fibrillation. 
  • A non-experimental study of oral anticoagulation therapy initiation before and after national patient safety goals. 
  • A novel amiodarone-eluting biological glue for reducing postoperative atrial fibrillation: first animal trial. 
  • A novel implantable cardiac telemetry system for studying atrial fibrillation 
  • A pint of sweat will save a gallon of blood: a call for randomized trials of anticoagulation in end-stage renal disease. 
  • A proposal for new clinical concepts in the management of atrial fibrillation. 
  • A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. 
  • A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. 
  • A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation. 
  • A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE. 
  • A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation. 
  • A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. 
  • A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. 
  • ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration with the Heart Rhythm Society. 
  • ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. 
  • ACP Journal Club. Apixaban reduced stroke or systemic embolism in AF more than warfarin regardless of type or duration of AF. 
  • ACP Journal Club. In atrial fibrillation, the ATRIA risk score better predicted stroke than CHADS2 and CHA2DS2-VASc scores. 
  • ACP Journal Club: pooled RCTs: β-blockers reduce mortality in heart failure patients with sinus rhythm but not in those with AF. 
  • AIM-AF: A Physician Survey in the United States and Europe. 
  • Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial. 
  • Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities. 
  • Ablation of atrial fibrillation during coronary artery bypass grafting: Late outcomes in a Medicare population. 
  • Ablation of persistent atrial fibrillation: Challenges and solutions. 
  • Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. 
  • Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke. 
  • Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) registry. 
  • Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. 
  • Acute Ischemic Stroke, Depressed Left Ventricular Ejection Fraction, and Sinus Rhythm: Prevalence and Practice Patterns. 
  • Acute echocardiographic and hemodynamic response to his-bundle pacing in patients with first-degree atrioventricular block. 
  • Acute heart failure associated with high admission blood pressure--a distinct vascular disorder? 
  • Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. 
  • Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. 
  • Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. 
  • Adaptive servo-ventilation reduces atrial fibrillation burden in patients with heart failure and sleep apnea. 
  • Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. 
  • Adenosine-induced flow arrest to facilitate intracranial aneurysm clip ligation: dose-response data and safety profile. 
  • Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation. 
  • Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable. 
  • Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. 
  • Adiponectin: an accurate biomarker for patients at risk for atrial fibrillation? 
  • Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. 
  • Advances in Cardiac Electrophysiology. 
  • Advances in Stroke: Treatments-Preventive. 
  • Advances in prevention and health services delivery 2010-2011. 
  • Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop. 
  • Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. 
  • Adverse effects of nifedipine therapy on hypertrophic obstructive cardiomyopathy. 
  • Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. 
  • Altering the topology of gap junctions a major therapeutic target for atrial fibrillation. 
  • Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. 
  • Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. 
  • American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. 
  • Amiodarone treatment in atrial fibrillation and the risk of incident cancers: A nationwide observational study. 
  • Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • An adverse reaction to a medication given to treat an adverse reaction: a teachable moment. 
  • An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS). 
  • An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. 
  • An unusual cardiac defect in a patient with clinical features overlapping between cardiofaciocutaneous and Noonan syndromes. 
  • Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. 
  • Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Anesthetic management of an AAI pacemaker patient with paroxysmal atrial fibrillation during colorectal surgery. 
  • Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. 
  • Angiotensin-converting enzyme inhibitors: a new therapy for atrial fibrillation? 
  • Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease. 
  • Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. 
  • Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. 
  • Anticoagulation Resumption After Stroke from Atrial Fibrillation. 
  • Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study. 
  • Anticoagulation after Ablation for Atrial Fibrillation. 
  • Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada. 
  • Anticoagulation in Patients With Atrial Fibrillation in the Setting of Prior Hemorrhage: An Ongoing Dilemma. 
  • Anticoagulation in atrial fibrillation. 
  • Anticoagulation in heart failure: current status and future direction. 
  • Anticoagulation strategies for the management of postoperative atrial fibrillation. 
  • Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. 
  • Anticoagulation-Related Major Bleeding in Patients With Atrial Fibrillation: Looking Behind the Curtain. 
  • Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. 
  • Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. 
  • Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention-Reply. 
  • Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. 
  • Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. 
  • Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation. 
  • Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. 
  • Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. 
  • Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot. 
  • Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. 
  • Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. 
  • Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy. 
  • Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). 
  • Antithrombotic therapy in atrial fibrillation. 
  • Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. 
  • Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. 
  • Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. 
  • Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. 
  • Antithrombotic treatment strategies after PCI. 
  • Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5). 
  • Aorto-coronary bypass graft surgery in a patient on home hemodialysis. 
  • Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. 
  • Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. 
  • Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. 
  • Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. 
  • Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. 
  • Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. 
  • Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. 
  • Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. 
  • Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. 
  • Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. 
  • Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. 
  • Apixaban to prevent stroke in patients with atrial fibrillation: a review. 
  • Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. 
  • Apixaban versus warfarin in patients with atrial fibrillation. 
  • Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Apixaban: an emerging oral factor Xa inhibitor. 
  • Appearance of atrial rhythm with absent P wave in longstanding atrial fibrillation. 
  • Application of net reclassification index to non-nested and point-based risk prediction models: a review. 
  • Applying antithrombotic therapies to improve outcomes in patients with atrial fibrillation. 
  • Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch: Findings From the Apple Heart Study. 
  • Arrhythmias in children having a single left superior vena cava and minimal structural heart disease. 
  • Arrhythmic Burden and the Risk of Cardiovascular Outcomes in Patients With Paroxysmal Atrial Fibrillation and Cardiac Implanted Electronic Devices. 
  • Arrhythmogenic right ventricular cardiomyopathy: arrhythmias upstream and downstream. 
  • Assessing right atrial function in pulmonary hypertension: window to the soul of the right heart? 
  • Assessing the incremental predictive performance of novel biomarkers over standard predictors. 
  • Assessment of Device-Related Thrombus and Associated Clinical Outcomes With the WATCHMAN Left Atrial Appendage Closure Device for Embolic Protection in Patients With Atrial Fibrillation (from the PROTECT-AF Trial). 
  • Assessment of ECG during hybrid comprehensive telerehabilitation in heart failure patients-Subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) randomized clinical trial. 
  • Assessment of LV Myocardial Scar Before Atrial Fibrillation Ablation. 
  • Assessment of Trends in Guideline-Based Oral Anticoagulant Prescription for Patients With Ischemic Stroke and Atrial Fibrillation in China. 
  • Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial. 
  • Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Association Between Hospital-Documented Atrial Fibrillation and Central Retinal Artery Occlusion. 
  • Association Between Inappropriately Dosed Anticoagulation Therapy With Stroke Severity and Outcomes in Patients With Atrial Fibrillation. 
  • Association Between Left Atrial Appendage Occlusion and Readmission for Thromboembolism Among Patients With Atrial Fibrillation Undergoing Concomitant Cardiac Surgery. 
  • Association Between Sex and Treatment Outcomes of Atrial Fibrillation Ablation Versus Drug Therapy: Results From the CABANA Trial. 
  • Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. 
  • Association between economic and arrhythmic burden of paroxysmal atrial fibrillation in patients with cardiac implanted electronic devices. 
  • Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. 
  • Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation. 
  • Association of Chronic Renal Insufficiency With In-Hospital Outcomes in Primary Atrial Fibrillation Hospitalizations. 
  • Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. 
  • Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. 
  • Association of P-Wave Axis With Incident Atrial Fibrillation in Diabetes Mellitus (from the ACCORD Trial). 
  • Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. 
  • Association of Preoperative Renin-Angiotensin System Inhibitors With Prevention of Postoperative Atrial Fibrillation and Adverse Events: A Systematic Review and Meta-analysis. 
  • Association of Race and Ethnicity With Oral Anticoagulation and Associated Outcomes in Patients With Atrial Fibrillation: Findings From the Get With The Guidelines-Atrial Fibrillation Registry. 
  • Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. 
  • Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. 
  • Association of circulating cardiac biomarkers with electrocardiographic abnormalities in chronic kidney disease. 
  • Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. 
  • Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study. 
  • Associations Between Surgical Ablation and Operative Mortality After Mitral Valve Procedures. 
  • Associations between anticoagulation therapy and risks of mortality and readmission among patients with heart failure and atrial fibrillation. 
  • Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. 
  • Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. 
  • Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. 
  • Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. 
  • Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. 
  • Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy. 
  • Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction. 
  • Atrial Fibrillation and Diabetes Mellitus: Can We Modify Stroke Risk Through Glycemic Control? 
  • Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. 
  • Atrial Fibrillation and Heart Failure: In This Challenge Lies Opportunity. 
  • Atrial Fibrillation and Heart Failure: Too Much Talk and Not Enough Action. 
  • Atrial Fibrillation and Ischemic Stroke With the Amyloidogenic V122I Transthyretin Variant Among Black Americans. 
  • Atrial Fibrillation and Percutaneous Coronary Intervention. 
  • Atrial Fibrillation and Risk of ESRD in Adults with CKD. 
  • Atrial Fibrillation in Cancer Patients: Recognizing Gaps in Care. 
  • Atrial arrhythmias after pulmonary thromboendarterectomy. 
  • Atrial arrhythmias during chronic follow-up of surgery for complex congenital heart disease. 
  • Atrial branch coronary artery stenosis as a mechanism for atrial fibrillation. 
  • Atrial ejection force: a noninvasive assessment of atrial systolic function. 
  • Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug? 
  • Atrial fibrillation ablation in practice: assessing CABANA generalizability. 
  • Atrial fibrillation ablation using a closed irrigation radiofrequency ablation catheter. 
  • Atrial fibrillation after cardiac surgery/cardiopulmonary bypass is associated with monocyte activation. 
  • Atrial fibrillation after cardiac surgery: clinical update on mechanisms and prophylactic strategies. 
  • Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors. 
  • Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. 
  • Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction. 
  • Atrial fibrillation and kidney disease: stuck outside the CABANA. 
  • Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. 
  • Atrial fibrillation and mortality risk: seeing the big picture. 
  • Atrial fibrillation and obstructive lung disease: Don't fear the β-blocker. 
  • Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: data from the Mode Selection Trial (MOST). 
  • Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Atrial fibrillation and risk of postoperative complications. 
  • Atrial fibrillation and stroke severity: expanding the mechanistic exemplar, clinical phenotype, and goals of anticoagulant pharmacotherapy. 
  • Atrial fibrillation and stroke: it's not necessarily all about the rhythm. 
  • Atrial fibrillation and sudden cardiac death: is heart failure the middleman? 
  • Atrial fibrillation burden and heart failure: Data from 39,710 individuals with cardiac implanted electronic devices. 
  • Atrial fibrillation burden, progression, and the risk of death: a case-crossover analysis in patients with cardiac implantable electronic devices. 
  • Atrial fibrillation correction surgery: lessons from the Society of Thoracic Surgeons National Cardiac Database. 
  • Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. 
  • Atrial fibrillation in an African-American cohort: The Jackson Heart Study. 
  • Atrial fibrillation in heart failure: what should we do? 
  • Atrial fibrillation in the preexcitation syndrome. 
  • Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Atrial fibrillation is an independent risk factor for heart failure hospitalization in heart failure with preserved ejection fraction. 
  • Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. 
  • Atrial fibrillation mapping strategies: The hunt is on. 
  • Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. 
  • Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. 
  • Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. 
  • Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention. 
  • Atrial fibrillation: conventional wisdom reappraised. 
  • Atrial fibrillation: rate control versus maintenance of sinus rhythm. 
  • Atrial fibrillation: what do we know about screening and what do we not know about treatment? 
  • Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). 
  • Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias. 
  • B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. 
  • B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. 
  • Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. 
  • Behavior of AV synchrony pacing mode in a leadless pacemaker during variable AV conduction and arrhythmias. 
  • Benefits of Emergency Departments' Contribution to Stroke Prophylaxis in Atrial Fibrillation: The EMERG-AF Study (Emergency Department Stroke Prophylaxis and Guidelines Implementation in Atrial Fibrillation). 
  • Biatrial maze procedure versus pulmonary vein isolation for atrial fibrillation during mitral valve surgery: New analytical approaches and end points. 
  • Bimodal distribution of atrial fibrillation burden in 3 distinct cohorts: What is 'paroxysmal' atrial fibrillation? 
  • Biomarker-based risk prediction in the community. 
  • Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. 
  • Biomarkers and the prediction of atrial fibrillation: state of the art. 
  • Biomarkers in atrial fibrillation: a clinical review. 
  • Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect. 
  • Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. 
  • Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. 
  • Bleeding and risk for future cardiovascular events in patients with atrial fibrillation on oral anticoagulation: major bleeding is a major problem. 
  • Blending Quality Improvement and Research Methods for Implementation Science, Part II: Analysis of the Quality of Implementation. 
  • Blending Quality Improvement and Research Methods for Implementation Science, Part III: Analysis of the Effectiveness of Implementation. 
  • Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). 
  • Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. 
  • Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. 
  • Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation. 
  • Bridging Anticoagulation in Patients with Atrial Fibrillation. 
  • Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. 
  • Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. 
  • Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. 
  • Burden of preoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. 
  • Bystander Ethics and Good Samaritanism: A Paradox for Learning Health Organizations. 
  • CASE 6--2012: suspected amiodarone hepatotoxicity after cardiac surgery. 
  • CHA2DS2-VAS(C) and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation. 
  • CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. 
  • COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. 
  • Calcified Pipes: You Better Call the Electrician Too. 
  • Call me maybe? The right time and place for BPAs in EHRs. 
  • Can catheter ablation of atrial fibrillation reverse heart failure with preserved ejection fraction? 
  • Can continuous quality improvement be assessed using randomized trials? [see comment]. 
  • Can polymorphisms predict response to antiarrhythmic drugs in atrial fibrillation? 
  • Cannabis use disorder among atrial fibrillation admissions, 2008-2018. 
  • Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study. 
  • Cardiac pacing strategies and post-implantation risk of atrial fibrillation and heart failure events in sinus node dysfunction patients: a collaborative analysis of over 6000 patients. 
  • Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. 
  • Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. 
  • Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage. 
  • Cardiopulmonary Emergencies in Older Adults. 
  • Cardiovascular Disease and HIV: Pathophysiology, Treatment Considerations, and Nursing Implications. 
  • Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). 
  • Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. 
  • Cardioversion and subsequent quality of life and natural history of atrial fibrillation. 
  • Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. 
  • Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. 
  • Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. 
  • Cases from the Osler Medical Service at Johns Hopkins University. Digitalis toxicity with bidirectional ventricular tachycardia. 
  • Catheter Ablation Compared With Drug Therapy for Atrial Fibrillation-Reply. 
  • Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 
  • Catheter Ablation of Atrial Fibrillation With and Without On-Site Cardiothoracic Surgery. 
  • Catheter Ablation of Atrial Fibrillation in U.S. Community Practice--Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. 
  • Catheter ablation of atrial fibrillation in cardiac amyloidosis. 
  • Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. 
  • Catheter ablation of atrial fibrillation in the elderly. 
  • Catheter ablation of atrial fibrillation in the elderly: where do we stand? 
  • Catheter ablation of atrial fibrillation with heart failure: An updated meta-analysis of randomized trials. 
  • Catheter ablation of rotational activity in atrial fibrillation: A barren oasis? 
  • Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. 
  • Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. 
  • Cerebral magnetic resonance findings in asymptomatic patients after atrial fibrillation catheter ablation: cause for alarm or further study? 
  • Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management. 
  • Challenges in atrial fibrillation beyond stroke prevention: keeping patients out of the hospital. 
  • Change Is Not Always Good. 
  • Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. 
  • Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation. 
  • Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? 
  • Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). 
  • Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. 
  • Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. 
  • Chocolate and prevention of atrial fibrillation: what is bad for the pancreas might be good for the atria? 
  • Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. 
  • Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. 
  • Chromosome 4q25 variants and biomarkers of myocardial fibrosis in patients with atrial fibrillation. 
  • Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. 
  • Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. 
  • Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy-Reply. 
  • Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. 
  • Clinical Trials in Atrial Fibrillation: Lessons From the Box Score. 
  • Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease. 
  • Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. 
  • Clinical cardiac electrophysiology fellowship teaching objectives for the new millennium. 
  • Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya. 
  • Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. 
  • Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. 
  • Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. 
  • Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. 
  • Clinical outcomes and treatment patterns among Medicare patients with nonvalvular atrial fibrillation (NVAF) and chronic kidney disease. 
  • Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. 
  • Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. 
  • Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. 
  • Clinical predictors and hemodynamic consequences of elevated peripheral chemosensitivity in optimally treated men with chronic systolic heart failure. 
  • Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. 
  • Clopidogrel plus aspirin in atrial fibrillation. 
  • Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. 
  • Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke? 
  • Cognitive dysfunction in atrial fibrillation. 
  • Cognitive function and anticoagulation control in patients with atrial fibrillation. 
  • Cohort profile: patient characteristics and quality-of-life measurements for newly-referred patients with atrial fibrillation-Keio interhospital Cardiovascular Studies-atrial fibrillation (KiCS-AF). 
  • Combined use of warfarin and oral P2Y12 inhibitors in patients with atrial fibrillation and acute coronary syndrome. 
  • Community impact of anticoagulation services: rationale and design of the Managing Anticoagulation Services Trial (MAST). 
  • Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. 
  • Comparative Effectiveness of Left Atrial Appendage Occlusion Versus Oral Anticoagulation by Sex. 
  • Comparative Safety and Effectiveness of Sotalol Versus Dronedarone After Catheter Ablation for Atrial Fibrillation. 
  • Comparative Safety of Transcatheter LAAO With the First-Generation Watchman and Next-Generation Watchman FLX Devices. 
  • Comparative effectiveness of pharmacotherapies for prevention of atrial fibrillation following coronary artery bypass surgery. 
  • Comparative effectiveness of warfarin and new anticoagulants. 
  • Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. 
  • Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. 
  • Comparative health services research across populations: the unused opportunities in big data. 
  • Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. 
  • Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry. 
  • Comparison of Risk of Atrial Fibrillation in Black Versus White Patients After Coronary Artery Bypass Grafting. 
  • Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement. 
  • Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. 
  • Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. 
  • Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. 
  • Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. 
  • Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. 
  • Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs. 
  • Completion of guideline-recommended initial evaluation of atrial fibrillation. 
  • Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. 
  • Considerations for Long-Term Anticoagulation for Stroke Prevention in Patients With Atrial Fibrillation and Cancer. 
  • Consumer-led screening for atrial fibrillation using consumer-facing wearables, devices and apps: A survey of health care professionals by AF-SCREEN international collaboration. 
  • Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry. 
  • Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? 
  • Continuous anticoagulation with catheter ablation: answers and questions. 
  • Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series. 
  • Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. 
  • Contrast M-mode ultrasonography of the inferior vena cava. 
  • Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. 
  • Controversy Regarding the Beneficial Effect of Bariatric Surgery on the Incidence of Atrial Fibrillation. 
  • Correlation between AV synchrony and device collected AM-VP sequence counter in atrioventricular synchronous leadless pacemakers: A real-world assessment. 
  • Cost analysis of periprocedural imaging in patients undergoing catheter ablation for atrial fibrillation. 
  • Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. 
  • Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial. 
  • Cost-Effectiveness of Extended Electrocardiogram Monitoring for Atrial Fibrillation After Stroke: A Systematic Review. 
  • Cost-Effectiveness of Left Atrial Appendage Occlusion: A Case Based on Facts Not in Evidence? 
  • Cost-effectiveness of dual-chamber pacing compared with ventricular pacing for sinus node dysfunction. 
  • Cost-effectiveness of ximelagatran for stroke prevention. 
  • Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. 
  • Critical mitral stenosis causing ischemic hepatic failure. Successful treatment by percutaneous balloon mitral valvotomy. 
  • Cryoablation for atrial fibrillation and antiarrhythmic drug pretreatment: a single referral center experience. 
  • Cryoablation of atrial fibrillation. 
  • D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. 
  • Dabigatran Compared With Rivaroxaban vs Warfarin. 
  • Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. 
  • Dabigatran versus warfarin in patients with mechanical heart valves. 
  • Dabigatran-related coagulopathy: when can we assume the effect has "worn off"? 
  • Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. 
  • Deep learning approaches for plethysmography signal quality assessment in the presence of atrial fibrillation. 
  • Deep learning model to quantify left atrium volume on routine non-contrast chest CT and predict adverse outcomes. 
  • Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. 
  • Delayed recognition of Type II decompression sickness in a diver with chronic atrial fibrillation. 
  • Design and Rationale of a Phase 2 Study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation - The NOVA Study. 
  • Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure. 
  • Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study. 
  • Detection of Atrial Fibrillation After Central Retinal Artery Occlusion. 
  • Developing the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: a Cardiac Safety Research Consortium "Incubator" Think Tank. 
  • Development and validation of an automated algorithm for end point adjudication for a large U.S. national registry. 
  • Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. 
  • Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. 
  • Device-Related Thrombus After Left Atrial Appendage Occlusion: The Villain of the Piece. 
  • Device-Sizing and Associated Complications With Left Atrial Appendage Occlusion: Findings From the NCDR LAAO Registry. 
  • Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. 
  • Diagnosis-to-Ablation Time and Recurrence of Atrial Fibrillation Following Catheter Ablation: A Systematic Review and Meta-Analysis of Observational Studies. 
  • Diagnostic accuracy and performance of artificial intelligence in measuring left atrial volumes and function on multiphasic CT in patients with atrial fibrillation. 
  • Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men-Reply. 
  • Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry. 
  • Differences in Preferences Between Clinicians and Patients for the Use and Dosing of Direct Oral Anticoagulants for Atrial Fibrillation. 
  • Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. 
  • Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. 
  • Digoxin and Mortality in Patients With Atrial Fibrillation. 
  • Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Direct His bundle pacing post AVN ablation. 
  • Direct Thrombin Inhibition During Left-Sided Catheter Ablation: More Than Just an Alternative? 
  • Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). 
  • Disease understanding in patients newly diagnosed with atrial fibrillation. 
  • Disentangling the risk of atrial fibrillation detected after ischemic stroke (AFDAS): A real challenge in clinical practice. 
  • Dissection of a quantitative trait locus for PR interval duration identifies Tnni3k as a novel modulator of cardiac conduction. 
  • Do anticoagulation management services improve care? Implications of the Managing Anticoagulation Services Trial. 
  • Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. 
  • Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry. 
  • Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials. 
  • Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. 
  • Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study. 
  • Does preoperative atrial fibrillation increase the risk for mortality and morbidity after coronary artery bypass grafting? 
  • Dofetilide dose reductions and discontinuations in women compared with men. 
  • Dose-adjusted warfarin: writing the prescription is only the beginning. 
  • Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. 
  • Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). 
  • Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Dronedarone and vitamin K antagonists: a review of drug-drug interactions. 
  • Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial. 
  • Dronedarone in high-risk permanent atrial fibrillation. 
  • Dropping P2Y12 inhibitors in patients with AF undergoing PCI? Not yet a SAFE bet. 
  • Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. 
  • Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. 
  • Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. 
  • Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. 
  • Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. 
  • Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. 
  • Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. 
  • Early ischaemic and haemorrhagic complications after atrial fibrillation-related ischaemic stroke: analysis of the IAC study. 
  • Early life predictors of atrial fibrillation-related mortality: evidence from the health and retirement study. 
  • Early management of atrial fibrillation to prevent cardiovascular complications. 
  • Early mortality after inpatient versus outpatient catheter ablation in patients with atrial fibrillation. 
  • Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Early-life antecedents of atrial fibrillation: place of birth and atrial fibrillation-related mortality. 
  • Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. 
  • Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. 
  • Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction. 
  • Editorial Commentary: Prevention and treatment of atrial fibrillation: Is hyperuricemia the next target? 
  • Editorial commentary: Atrial fibrillation ablation with cryoenergy: It׳s "Cool"; it׳s "Non-inferior"; Is it better? 
  • Editorial commentary: Pulsed field catheter ablation in atrial fibrillation: The promising future of an old technology. 
  • Editorial commentary: Sleeping on a treatment for atrial fibrillation? 
  • Edoxaban and the need for outcomes-based NOAC dosing. 
  • Edoxaban versus warfarin in patients with atrial fibrillation. 
  • Educational attainment is associated with atrial fibrillation symptom severity. 
  • Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial. 
  • Effect of Alteplase Use on Outcomes in Patients With Atrial Fibrillation: Analysis of the Initiation of Anticoagulation After Cardioembolic Stroke Study. 
  • Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. 
  • Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). 
  • Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. 
  • Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. 
  • Effect of Falls on Frequency of Atrial Fibrillation and Mortality Risk (from the REasons for Geographic And Racial Differences in Stroke Study). 
  • Effect of Known Atrial Fibrillation and Anticoagulation Status on the Prehospital Identification of Large Vessel Occlusion. 
  • Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: The STROKE-AF Randomized Clinical Trial. 
  • Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical Trial. 
  • Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis. 
  • Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). 
  • Effect of amiodarone-induced hyperthyroidism on left ventricular outflow obstruction after septal myectomy for hypertrophic cardiomyopathy. 
  • Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. 
  • Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. 
  • Effect of home testing of international normalized ratio on clinical events. 
  • Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. 
  • Effect of the 2014 atrial fibrillation guideline revisions on the proportion of patients recommended for oral anticoagulation. 
  • Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. 
  • Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. 
  • Effects of Ablation Versus Drug Therapy on Quality of Life by Sex in Atrial Fibrillation: Results From the CABANA Trial. 
  • Effects of acetyl strophanthidin on duration of atrial fibrillation in the neurally-intact and blockaded dog. 
  • Effects of alcohol on experimental atrial fibrillation. 
  • Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. 
  • Effects of atrial fibrillation on myocardial blood flow in the ischemic heart of the dog. 
  • Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized trial. 
  • Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation. 
  • Effects of cardiac glycosides on atrial contractile dysfunction after short-term atrial fibrillation. 
  • Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome. 
  • Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. 
  • Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. 
  • Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. 
  • Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. 
  • Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. 
  • Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. 
  • Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. 
  • Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). 
  • Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. 
  • Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. 
  • Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. 
  • Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. 
  • Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). 
  • Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. 
  • Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. 
  • Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. 
  • Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. 
  • Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). 
  • Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. 
  • Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. 
  • Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. 
  • Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. 
  • Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial. 
  • Efficacy of adjunctive ablation of complex fractionated atrial electrograms and pulmonary vein isolation for the treatment of atrial fibrillation: a meta-analysis of randomized controlled trials. 
  • Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. 
  • Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial. 
  • Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. 
  • Electrocardiographic P terminal force in lead V1, its components, and the association with stroke and atrial fibrillation or flutter. 
  • Electrocardiography Screening for Atrial Fibrillation: We Can Do Better. 
  • Electronic alerts to initiate anticoagulation dialogue in patients with atrial fibrillation. 
  • Electrophysiologic effects of disopyramide phosphate on sinus node function in patients with sinus node dysfunction. 
  • Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). 
  • End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. 
  • Epidemiology of new-onset atrial fibrillation following coronary artery bypass graft surgery. 
  • Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. 
  • Evaluating Discrimination of Risk Prediction Models: The C Statistic. 
  • Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. 
  • Evaluation of left atrial appendage anatomy and function in recent-onset atrial fibrillation by transesophageal echocardiography. 
  • Evaluation of outpatients experiencing implantable cardioverter defibrillator shocks associated with minimal symptoms. 
  • Evaluation of several methods for computing stroke volume from central aortic pressure. 
  • Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. 
  • Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. 
  • Evidence Builds for Catheter Ablation for Atrial Fibrillation and Heart Failure. 
  • Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. 
  • Exploration of PCSK9 as a Cardiovascular Risk Factor: Is There a Link to the Platelet? 
  • Exploring patient-provider decision-making for use of anticoagulation for stroke prevention in atrial fibrillation: Results of the INFORM-AF study. 
  • Expression of heat shock proteins in myocardium of patients with atrial fibrillation. 
  • Extracellular vesicles in atrial fibrillation and stroke. 
  • FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial. 
  • Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AF. 
  • Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). 
  • Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). 
  • Factors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillation. 
  • Familial clustering and subsequent incidence of atrial fibrillation among first-degree relatives in Denmark. 
  • Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. 
  • Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Feasibility of near real-time lesion assessment during radiofrequency catheter ablation in humans using acoustic radiation force impulse imaging. 
  • Flavonoid intake and its association with atrial fibrillation. 
  • Fluid management in cardiac surgery: colloid or crystalloid? 
  • Freedom from atrial fibrillation after catheter ablation: Survival of the fittest. 
  • Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). 
  • Frontiers of Upstream Stroke Prevention and Reduced Stroke Inequity Through Predicting, Preventing, and Managing Hypertension and Atrial Fibrillation: A Call to Action From the Value in Healthcare Initiative's Predict & Prevent Learning Collaborative. 
  • G protein-coupled receptor kinase 5 gene polymorphisms are associated with postoperative atrial fibrillation after coronary artery bypass grafting in patients receiving β-blockers. 
  • GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. 
  • Gastroesophageal reflux and atrial fibrillation: is there any correlation? 
  • Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. 
  • Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Gender Differences in Clinical Outcomes after Catheter Ablation of Atrial Fibrillation. 
  • Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. 
  • Gene signatures of postoperative atrial fibrillation in atrial tissue after coronary artery bypass grafting surgery in patients receiving β-blockers. 
  • Gene-gene Interaction Analyses for Atrial Fibrillation. 
  • Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice. 
  • Genetic Investigation Into the Differential Risk of Atrial Fibrillation Among Black and White Individuals. 
  • Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL). 
  • Genome-wide association study of new-onset atrial fibrillation after coronary artery bypass grafting surgery. 
  • Geographic variation in the use of catheter ablation for atrial fibrillation among Medicare beneficiaries. 
  • Get With The Guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. 
  • Getting (Left Atrial Appendage) Closure With Kidney Disease. 
  • Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. 
  • Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Guideline-Concordant Antiarrhythmic Drug Use in the Get With The Guidelines-Atrial Fibrillation Registry. 
  • Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. 
  • HRS/ACCF expert consensus statement on pacemaker device and mode selection. Developed in partnership between the Heart Rhythm Society (HRS) and the American College of Cardiology Foundation (ACCF) and in collaboration with the Society of Thoracic Surgeons. 
  • Harmonized outcome measures for use in atrial fibrillation patient registries and clinical practice: Endorsed by the Heart Rhythm Society Board of Trustees. 
  • Healthcare utilization and cost in patients with atrial fibrillation and heart failure undergoing catheter ablation. 
  • Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation. 
  • Heart Failure Complicated by Atrial Fibrillation: Don't Bury the Beta-Blockers Just Yet. 
  • Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report. 
  • Heart Rhythm Society Atrial Fibrillation Centers of Excellence Study: A survey analysis of stakeholder practices, needs, and barriers. 
  • Heart Watch Study: protocol for a pragmatic randomised controlled trial. 
  • Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization. 
  • Heart rate is associated with progression of atrial fibrillation, independent of rhythm. 
  • Heart Failure and Atrial Fibrillation, Like Fire and Fury. 
  • Heparins: their established role in acute coronary syndromes and perspectives in atrial fibrillation. 
  • Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. 
  • High prevalence of symptomatic bradyarrhythmias due to atrioventricular node-fascicular and sinus node-atrial disease in patients with mitral anular calcification. 
  • High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. 
  • Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. 
  • Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. 
  • History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. 
  • History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. 
  • Home monitoring of warfarin effects. 
  • Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. 
  • Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. 
  • Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. 
  • How country-specific should a country-specific cost-effectiveness analysis be? 
  • How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline. 
  • Iatrogenic left atrial tachycardias: where are we? 
  • Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. 
  • Images in cardiovascular medicine. Noninvasive characterization of left atrial mass. 
  • Impact of Atrial Fibrillation on In-Hospital Mortality and Thromboembolic Complications after Left Ventricular Assist Device Implantation. 
  • Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation. 
  • Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. 
  • Impact of comorbidities on ischemic stroke outcomes in women. 
  • Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. 
  • Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. 
  • Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. 
  • Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. 
  • Impedance Guided Radiofrequency Ablation for Atrial Fibrillation: Something Old Is New Again. 
  • Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. 
  • Implications of the LEGACY trial on US Atrial Fibrillation Patients: An NCDR Research to Practice (R2P) Project. 
  • Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. 
  • Improvement in use of anticoagulation therapy in patients with ischemic stroke: results from Get With The Guidelines-Stroke. 
  • Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both? 
  • Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. 
  • In patients with MI, new-onset or existing AF increased risk for CV events at 90 days. 
  • In search for an optimal antithrombotic regimen in patients with atrial fibrillation undergoing stenting. 
  • Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. 
  • Incidence and prognostic significance of chronic atrial fibrillation among 5,839 consecutive patients with acute myocardial infarction. The SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. 
  • Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. 
  • Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. 
  • Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry. 
  • Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. 
  • Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. 
  • Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. 
  • Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). 
  • Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. 
  • Independent predictors of stroke in patients with atrial fibrillation: a systematic review. 
  • Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry. 
  • Indications for pacing in the treatment of bradyarrhythmias. Report of an independent study group. 
  • Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators. 
  • Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. 
  • Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. 
  • Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. 
  • Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. 
  • Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. 
  • Influence of atrial fibrillation type on outcomes of ablation vs. drug therapy: results from CABANA. 
  • Influence of chronic kidney disease on warfarin therapy for atrial fibrillation. 
  • Initial anesthetic experience during combined epicardial-endocardial treatment of atrial fibrillation. 
  • Initial independent outcomes from focal impulse and rotor modulation ablation for atrial fibrillation: multicenter FIRM registry. 
  • Insulin Therapy and Stroke Risk in Patients With Diabetes and Atrial Fibrillation: Guilty by Association? 
  • Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. 
  • Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. 
  • Interaction between digoxin and dronedarone in the PALLAS trial. 
  • Interaction of Blood Pressure and Glycemic Status in Developing Cardiovascular Disease: Analysis of a Nationwide Real-World Database. 
  • Interactions between extracellular stimuli and excitation waves in an atrial reentrant loop. 
  • Interatrial Stent to Treat Stiff Left Atrium Syndrome. 
  • Internal cardioversion in two patients with atrial fibrillation refractory to external cardioversion. 
  • International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. 
  • International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. 
  • International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. 
  • Interpreting incremental value of markers added to risk prediction models. 
  • Interpreting the Results of Intention-to-Treat, Per-Protocol, and As-Treated Analyses of Clinical Trials. 
  • Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough? 
  • Intersection of atrial fibrillation and heart failure with mildly reduced and preserved ejection fraction in >400 000 participants in the Get With The Guidelines-Heart Failure Registry. 
  • Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. 
  • Intracerebral haemorrhage, atrial fibrillation, and anticoagulation - Authors' reply. 
  • Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. 
  • Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. 
  • Intraoperative Magnesium Administration Does Not Reduce Postoperative Atrial Fibrillation After Cardiac Surgery. 
  • Intravenous amiodarone or magnesium sulphate is not cost-beneficial prophylaxis for atrial fibrillation after coronary artery bypass surgery. 
  • Is There Still a Role for Digoxin in the Management of Atrial Fibrillation? 
  • Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. 
  • Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis. 
  • Is newer better? Propafenone versus quinidine for conversion of atrial fibrillation. 
  • Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? 
  • Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure? 
  • Is there a mortality benefit of atrial fibrillation ablation? 
  • Is there a period of liability with initiation of warfarin in patients with atrial fibrillation? 
  • Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. 
  • Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study. 
  • Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation. 
  • Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Lack of trophic pancreatic effects in humans with long-term administration of ximelagatran. 
  • Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. 
  • Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. 
  • Left Atrial Appendage Closure for Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation: the LAA-CAA Cohort. 
  • Left Atrial Appendage Electrical Isolation for Treatment of Recurrent Atrial Fibrillation: A Meta-Analysis. 
  • Left Atrial Appendage Morphology Improves Prediction of Stagnant Flow and Stroke Risk in Atrial Fibrillation. 
  • Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis. 
  • Left Atrial Volume Index Is Associated With Cardioembolic Stroke and Atrial Fibrillation Detection After Embolic Stroke of Undetermined Source. 
  • Left atrial appendage anatomy and function: short term response to sustained atrial fibrillation. 
  • Left atrial appendage characteristics and the risk of stroke: Sorting out the contenders from the pretenders. 
  • Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation. 
  • Left atrial appendage occlusion: rationale, evidence, devices, and patient selection. 
  • Left atrial appendage to great cardiac vein fistula complicating watchman left atrial appendage closure. 
  • Left atrial remodeling: shape before size? 
  • Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Letter by Hess et al Regarding Article, "How to Manage Occult Atrial Fibrillation Detected on Long-Term Monitoring". 
  • Letter to the Editor: Managing Dabigatran-Related Bleeding. 
  • Life-Threatening Event Risk in Children With Wolff-Parkinson-White Syndrome: A Multicenter International Study. 
  • Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation. 
  • Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. 
  • Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease. 
  • Long-term oral anticoagulant after catheter ablation for atrial fibrillation. 
  • Long-term outcomes after isolated aortic valve replacement in octogenarians: a modern perspective. 
  • Long-term outcomes following development of new-onset atrial fibrillation during sepsis. 
  • Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 
  • MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial. 
  • Machine learning does not improve upon traditional regression in predicting outcomes in atrial fibrillation: an analysis of the ORBIT-AF and GARFIELD-AF registries. 
  • Machine learning in 'big data': handle with care. 
  • Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF. 
  • Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. 
  • Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. 
  • Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. 
  • Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. 
  • Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. 
  • Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. 
  • Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. 
  • Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation. 
  • Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). 
  • Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. 
  • Management of atrial fibrillation in older patients: A network meta-analysis of randomized controlled trials. 
  • Management of atrial fibrillation. 
  • Management of atrial fibrillation. 
  • Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. 
  • Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 
  • Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. 
  • Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry. 
  • Measurement of aortic blood flow in man by the computed pressure derivative method. 
  • Measurements of the left atrium and pulmonary veins for analysis of reverse structural remodeling following cardiac ablation therapy. 
  • Mechanism and magnitude of bipolar electrogram directional sensitivity: Characterizing underlying determinants of bipolar amplitude. 
  • Mechanisms of atrial fibrillation and action of drugs used in its management. 
  • Medical treatment for stroke prevention. 
  • Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. 
  • Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites. 
  • Meta-analysis identifies six new susceptibility loci for atrial fibrillation. 
  • Meta-analysis of the effect of radiofrequency catheter ablation on left atrial size, volumes and function in patients with atrial fibrillation. 
  • Midregional Pro-Atrial Natriuretic Peptide and Atrial Fibrillation: Interesting Association or Practice Changing? 
  • Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. 
  • Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving Hope. 
  • Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. 
  • Minimum energy single-shock internal atrial defibrillation in sheep. 
  • Minitransseptal versus left atrial approach to the mitral valve: a comparison of outcomes. 
  • Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement? 
  • Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. 
  • Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation: Systematic review and network meta-analysis. 
  • More bad news for cardiac resynchronization therapy in atrial fibrillation patients: what to do? 
  • Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. 
  • Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. 
  • Multi-ethnic genome-wide association study for atrial fibrillation. 
  • Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. 
  • Mutation E169K in junctophilin-2 causes atrial fibrillation due to impaired RyR2 stabilization. 
  • N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). 
  • Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. 
  • National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure. 
  • Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. 
  • Navigating the treacherous waters of antithrombotic therapies in patients with atrial fibrillation and coronary artery disease: Lessons from AUGUSTUS. 
  • Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. 
  • Net reclassification index at event rate: properties and relationships. 
  • Neural substrate for atrial fibrillation: implications for targeted parasympathetic blockade in the posterior left atrium. 
  • Neuromodulation therapy for atrial fibrillation. 
  • New Treatment Options Fail to Close the Anticoagulation Gap in Atrial Fibrillation. 
  • New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance. 
  • New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. 
  • New paradigms in cardiovascular medicine: emerging technologies and practices: perioperative genomics. 
  • New-onset atrial fibrillation after acute myocardial infarction and its relation to admission biomarkers (from the TRIUMPH registry). 
  • New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. 
  • New-onset postoperative atrial fibrillation impact on 5-year clinical outcomes and costs. 
  • Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. 
  • Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation. 
  • Non-Vitamin K Antagonists Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review and Meta-Analysis. 
  • Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. 
  • Non-vitamin K antagonist oral anticoagulants in cardioversion of atrial fibrillation: a network meta-analysis. 
  • Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. 
  • North American Thrombosis Forum, AF Action Initiative Consensus Document. 
  • Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. 
  • Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. 
  • Novel oral anticoagulants in gastroenterology practice. 
  • Novel oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis. 
  • Observations on the occurrence of atrial fibrillation in paroxysmal supraventricular tachycardia. 
  • Observations on the transition from intermittent to permanent atrial fibrillation. 
  • Obstructive sleep apnea is associated with increased rotor burden in patients undergoing focal impulse and rotor modification guided atrial fibrillation ablation. 
  • Occurrence of atrial fibrillation in patients with paroxysmal supraventricular tachycardia due to atrioventricular nodal reentry. 
  • Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. 
  • Omnipolar Versus Bipolar Electrode Mapping in Patients With Atrial Fibrillation Undergoing Catheter Ablation. 
  • On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. 
  • Opportunistic screening for atrial fibrillation in a rural area. 
  • Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. 
  • Oral Anticoagulation and Adverse Outcomes after Ischemic Stroke in Heart Failure Patients without Atrial Fibrillation. 
  • Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. 
  • Oral Anticoagulation in Patients with End Stage Renal Disease and Atrial Fibrillation: The Need to Evaluate Net Clinical Effect. 
  • Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. 
  • Oral anticoagulants in older adults with atrial fibrillation. 
  • Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs? 
  • Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. 
  • Oral anticoagulation: a step toward solving the puzzle of dementia related to atrial fibrillation? 
  • Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. 
  • Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. 
  • Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study. 
  • Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. 
  • Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. 
  • Outcomes after nonemergent electrical cardioversion for atrial arrhythmias. 
  • Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. 
  • Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. 
  • Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter. 
  • Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. 
  • Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry. 
  • Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. 
  • Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. 
  • Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. 
  • Outcomes of atrioesophageal fistula following catheter ablation of atrial fibrillation treated with surgical repair versus esophageal stenting. 
  • Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Outcomes of medicare beneficiaries with heart failure and atrial fibrillation. 
  • Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. 
  • Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). 
  • Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. 
  • Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation. 
  • P-wave indices and atrial fibrillation: cross-cohort assessments from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) study. 
  • Pacemaker Implantation After Mitral Valve Surgery With Atrial Fibrillation Ablation. 
  • Paradoxical Cerebral Air Embolism after Cardiac Ablation in Williams-Beuren Syndrome: A Clinico-Pathological Correlation. 
  • Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach. 
  • Patient characteristics, care patterns, and outcomes of atrial fibrillation associated hospitalizations in patients with chronic kidney disease and end-stage renal disease. 
  • Patient factors associated with quality of life in atrial fibrillation. 
  • Patient selection in heart failure with preserved ejection fraction clinical trials. 
  • Patient selection, pacing indications, and subsequent outcomes with de novo leadless single-chamber VVI pacing. 
  • Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. 
  • Patient-Reported Outcomes in Atrial Fibrillation Research: Results of a Clinicaltrials.gov Analysis. 
  • Patient-centered medical homes and oral anticoagulation therapy initiation. 
  • Patient-reported outcomes and subsequent management in atrial fibrillation clinical practice: Results from the Utah mEVAL AF program. 
  • Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. 
  • Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. 
  • Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. 
  • Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation. 
  • Patterns of Care for Atrial Fibrillation Before, During, and at Discharge From Hospitalization: From the Get With The Guidelines-Atrial Fibrillation Registry. 
  • Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. 
  • Patterns of care for first-detected atrial fibrillation: Insights from the Get With The Guidelines® - Atrial Fibrillation registry. 
  • Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. 
  • Patterns of oral anticoagulation use with cardioversion in clinical practice. 
  • Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. 
  • Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. 
  • Percutaneous left atrial appendage occlusion: A review of current devices, clinical evidence, patient selection, and post procedural antithrombotic management. 
  • Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. 
  • Pericardial fat is associated with atrial conduction: the Framingham Heart Study. 
  • Pericardial fat volume and incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis and Jackson Heart Study. 
  • Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. 
  • Perioperative Diastolic Dysfunction: A Comprehensive Approach to Assessment by Transesophageal Echocardiography. 
  • Perioperative Inotrope Therapy and Atrial Fibrillation Following Coronary Artery Bypass Graft Surgery: Evidence of a Racial Disparity. 
  • Perioperative Management of the Gynecologic Patient on Long-term Anticoagulation. 
  • Perioperative conduction disturbances after transcatheter aortic valve replacement. 
  • Perioperative morbidity and mortality in combined vs. staged approaches to carotid and coronary revascularization. 
  • Peripheral arterial disease is associated with an increased risk of atrial fibrillation in the elderly. 
  • Peripheral blood metabolite profiles associated with new onset atrial fibrillation. 
  • Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. 
  • Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAAO Registry. 
  • Periprocedural imaging and outcomes after catheter ablation of atrial fibrillation. 
  • Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. 
  • Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. 
  • Pharmacoeconomics of atrial fibrillation and stroke prevention. 
  • Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. 
  • Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. 
  • Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. 
  • Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. 
  • Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). 
  • Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. 
  • Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative Pan-Stakeholder Critical Path Registry Model: a Cardiac Safety Research Consortium "Incubator" Think Tank. 
  • Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. 
  • Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. 
  • Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. 
  • Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies. 
  • Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. 
  • Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. 
  • Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. 
  • Postcardiac surgery complications: association of acute renal dysfunction and atrial fibrillation. 
  • Postdischarge international normalized ratio testing and long-term clinical outcomes of patients with heart failure receiving warfarin: findings from the ADHERE registry linked to Medicare claims. 
  • Postoperative and Nonvalvular Atrial Fibrillation-Not So Different After All. 
  • Postoperative atrial fibrillation impacts on costs and one-year clinical outcomes: the Veterans Affairs Randomized On/Off Bypass Trial. 
  • Postoperative atrial fibrillation: Sex-specific characteristics and effect on survival. 
  • Postoperative atrial fibrillation: from mechanisms to treatment. 
  • Postoperative pericardial effusion, pericardiotomy, and atrial fibrillation: An explanatory analysis of the PALACS trial. 
  • Postprocedural Antithrombotic Therapy Following Left Atrial Appendage Occlusion: No Longer Adrift in Uncertainty? 
  • Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial. 
  • Practical management of anticoagulation in patients with atrial fibrillation. 
  • Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation. 
  • Pre-Diabetes and Stroke in Patients With Atrial Fibrillation: When Risk Begets Risk. 
  • Pre-operative atrial fibrillation and early right ventricular failure after left ventricular assist device implantation: a systematic review and meta-analysis. 
  • Precardiac surgery angiotensin-converting enzymes and mineralocorticoid blockers do not trump atrial fibrillation but possibly acute kidney injury: the value of a negative randomized study. 
  • Predicting AF recurrence after catheter ablation: Is it time to use the force? 
  • Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. 
  • Predicting atrial fibrillation and flutter using electronic health records. 
  • Predicting atrial fibrillation recurrence after ablation in patients with heart failure: Validity of the APPLE and CAAP-AF risk scoring systems. 
  • Predictive ability of perioperative atrial fibrillation risk indices in cardiac surgery patients: a retrospective cohort study. 
  • Predictive capability of left atrial size measured by CT, TEE, and TTE for recurrence of atrial fibrillation following radiofrequency catheter ablation. 
  • Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. 
  • Predictors and significance of atrial rhythm before and six months after percutaneous balloon mitral commissurotomy. 
  • Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. 
  • Predictors of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: A Prespecified Secondary Analysis of the STROKE AF Randomized Clinical Trial. 
  • Predictors of Cardiac Perforation With Catheter Ablation of Atrial Fibrillation. 
  • Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. 
  • Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. 
  • Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. 
  • Preoperative β-blocker use in coronary artery bypass grafting surgery: national database analysis. 
  • Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. 
  • Prestroke and Poststroke Antithrombotic Therapy in Patients With Atrial Fibrillation: Results From a Nationwide Cohort. 
  • Prevalence and Risk Factors of Atrial Fibrillation in Chinese Elderly: Results from the Chinese Longitudinal Healthy Longevity Survey. 
  • Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation. 
  • Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. 
  • Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). 
  • Prevalence of atrial fibrillation and association with clinical, sociocultural, and ancestral correlates among Hispanic/Latinos: The Hispanic Community Health Study/Study of Latinos. 
  • Prevalence of atrial fibrillation and stroke risk assessment based on telemedicine screening tools in a primary healthcare setting. 
  • Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. 
  • Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation). 
  • Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. 
  • Preventing Atrial Fibrillation After Cardiac Surgery: What Matters Most. 
  • Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus. 
  • Preventing Stroke in Patients With Atrial Fibrillation-A Steep Climb Away From Achieving Peak Performance. 
  • Preventing and Managing Bleeding With Anticoagulation for Atrial Fibrillation. 
  • Preventing heart failure in atrial fibrillation: In the middle of difficulty lies opportunity. 
  • Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 
  • Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism. 
  • Prevention of atrial fibrillation following cardiac surgery. 
  • Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. 
  • Previously unreported adverse reaction to encainide. 
  • Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. 
  • Primary care physician-reported secondary and tertiary stroke prevention practices. A comparison between the United States and the United Kingdom. 
  • Primary prevention of stroke. 
  • Procedural Patterns and Safety of Atrial Fibrillation Ablation: Findings From Get With The Guidelines-Atrial Fibrillation. 
  • Procedure characteristics and outcomes of atrial fibrillation ablation procedures using cryoballoon versus radiofrequency ablation: A report from the GWTG-AFIB registry. 
  • Processed electroencephalogram during donation after cardiac death. 
  • Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. 
  • Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. 
  • Prolonged Cardiac Monitoring and Stroke Recurrence: A Meta-analysis. 
  • Prolonged Cardiac Rhythm Monitoring and Secondary Stroke Prevention in Patients With Cryptogenic Cerebral Ischemia. 
  • Promise of factor Xa inhibition in atrial fibrillation. 
  • Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. 
  • Propensity matched comparison of outcomes in older and younger patients after coronary artery bypass graft surgery. 
  • Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. 
  • Pulmonary Vein Isolation Using the Visually Guided Laser Balloon: A Prospective, Multicenter, and Randomized Comparison to Standard Radiofrequency Ablation. 
  • Pulmonary Vein Isolation With a Pace Capture-Guided Approach: Durable or Debatable? 
  • Pulmonary vein contraction before and after radiofrequency ablation for atrial fibrillation. 
  • Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. 
  • Pulmonary vein isolation for the treatment of drug-refractory atrial fibrillation in adults with congenital heart disease. 
  • Pulmonary venous infarction after radiofrequency ablation for atrial fibrillation. 
  • Putting risk prediction in atrial fibrillation into perspective. 
  • Quality of Evidence Underlying the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines on the Management of Atrial Fibrillation. 
  • Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. 
  • Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. 
  • Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. 
  • Quality of care for atrial fibrillation among patients hospitalized for heart failure. 
  • Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care. 
  • Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. 
  • Quantifying the Impact of Atrial Fibrillation on Heart Failure-Related Patient-Reported Outcomes in the Utah mEVAL Program. 
  • Racial and ethnic differences in the prevalence, management, and outcomes in patients with atrial fibrillation: A systematic review. 
  • Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure. 
  • Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. 
  • Random and nonrandom behavior of symptomatic paroxysmal atrial fibrillation. 
  • Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway. 
  • Randomized Clinical Trials of Catheter Ablation of Atrial Fibrillation in Congestive Heart Failure: Knowns and Unmet Needs. 
  • Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. 
  • Ranolazine reduces atrial fibrillatory wave frequency. 
  • Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. 
  • Rate control in patients with chronic atrial fibrillation. 
  • Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. 
  • Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. 
  • Rates and predictors of hospital and emergency department care after catheter ablation of atrial fibrillation. 
  • Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. 
  • Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. 
  • Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. 
  • Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. 
  • Rationale, considerations, and goals for atrial fibrillation centers of excellence: A Heart Rhythm Society perspective. 
  • Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. 
  • Real-time 3-dimensional transesophageal echocardiography during left atrial radiofrequency catheter ablation for atrial fibrillation. 
  • Real-time monitoring of luminal esophageal temperature during left atrial radiofrequency catheter ablation for atrial fibrillation: observations about esophageal heating during ablation at the pulmonary vein ostia and posterior left atrium. 
  • Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Recent Advances in Lesion Formation for Catheter Ablation of Atrial Fibrillation. 
  • Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants and Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase-Reply. 
  • Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. 
  • Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. 
  • Recurrent Post-Ablation Paroxysmal Atrial Fibrillation Shares Substrates With Persistent Atrial Fibrillation : An 11-Center Study. 
  • ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor. 
  • Reduction in Inappropriate ICD Therapy in MADIT-RIT Patients Without History of Atrial Tachyarrhythmia. 
  • Reexamination of the Embolic Stroke of Undetermined Source Concept. 
  • Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF). 
  • Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial. 
  • Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). 
  • Relation of Serum Uric Acid and Cardiovascular Events in Young Adults Aged 20-49 Years. 
  • Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. 
  • Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. 
  • Relationship between atrial tachyarrhythmias and symptoms. 
  • Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. 
  • Relationships between emerging measures of heart failure processes of care and clinical outcomes. 
  • Remodeled cardiac calcium channels. 
  • Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. 
  • Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. 
  • Reply to the Editor- Contact force-sensing catheters and increased risk of atrioesophageal fistula: Is the tool to blame or the workmen? 
  • Reply: Are Rotors Markers of Substrate or a Mechanism of Perpetuation of Atrial Fibrillation? Increasing Data for Rotational Drivers of Human AF. 
  • Reply: Digoxin Use in Atrial Fibrillation: Minimizing and Refining its Use When Still Needed. 
  • Reply: Graphing Ratio Measures on Forest Plot. 
  • Reply: Higher N-terminal Pro-B-type natriuretic peptide may be related to very different conditions. 
  • Reply: Intracardiac Versus Transesophageal Echocardiography: If You Don't Compare Them You Don't Have the Answer. 
  • Reply: Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. 
  • Reproducibility of left atrial ablation with high-intensity focused ultrasound energy in a calf model. 
  • Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. 
  • Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. 
  • Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. 
  • Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report. 
  • Response by Fordyce et al to Letter Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF". 
  • Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". 
  • Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". 
  • Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". 
  • Response to the Letter to the Editor titled "Atrial fibrillation in patients with acute coronary syndromes". 
  • Restarting Therapeutic Anticoagulation After Elective Craniotomy for Patients with Chronic Atrial Fibrillation: A Review of the Literature. 
  • Restitution in mapping models with an arbitrary amount of memory. 
  • Results of the multicenter RENEWAL 3 AVT clinical study of cardiac resynchronization defibrillator therapy in patients with paroxysmal atrial fibrillation. 
  • Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials. 
  • Review: In noncardiac surgery, amiodarone, β-blocker, or statin prophylaxis reduces postoperative AF. 
  • Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines-Heart Failure. 
  • Rhythm control in atrial fibrillation. 
  • Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation. 
  • Rhythm control versus rate control for atrial fibrillation and heart failure. 
  • Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. 
  • Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. 
  • Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation. 
  • Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan　- Insights From GARFIELD-AF. 
  • Risk assessment for incident heart failure in individuals with atrial fibrillation. 
  • Risk assessment in atrial fibrillation: not all factors are created equal. 
  • Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients. 
  • Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. 
  • Risk markers of incident atrial fibrillation in patients with coronary heart disease. 
  • Risk of Ischemic Stroke in Patients With Atrial Fibrillation After Extracranial Hemorrhage. 
  • Risk of atrioesophageal fistula formation with contact force-sensing catheters. 
  • Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. 
  • Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. 
  • Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. 
  • Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. 
  • Risk profiles for acute health events after incident atrial fibrillation in patients with end-stage renal disease on hemodialysis. 
  • Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With the Guidelines-Stroke Program. 
  • Risk stratification for stroke in atrial fibrillation: a critique. 
  • Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. 
  • Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. 
  • Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. 
  • Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. Reply. 
  • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. 
  • Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. 
  • Rivaroxaban, an oral direct factor Xa inhibitor. 
  • Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. 
  • Road mapping ATLAS ACS 2: are we there yet? 
  • Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. 
  • SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. 
  • SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation: A Cluster-Randomized Study of Electronic Profiling and Messaging Combined With Academic Detailing for Providers Making Decisions About Anticoagulation in Patients With Atrial Fibrillation. 
  • Safe and Effective Anticoagulation: What Does Drug Concentration Add? 
  • Safety and Clinical Outcomes of Catheter Ablation of Atrial Fibrillation in Patients With Chronic Kidney Disease. 
  • Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. 
  • Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. 
  • Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. 
  • Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. 
  • Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. 
  • Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation. 
  • Safety and feasibility of same-day discharge for catheter ablation of atrial fibrillation: a systematic review and meta-analysis. 
  • Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. 
  • Screening for Atrial Fibrillation With a Wearable Device. 
  • Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. 
  • Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. 
  • Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. 
  • Seasonal Variation of Atrial Fibrillation Admission and Quality of Care in the United States. 
  • Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. 
  • Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-Get With the Guidelines. 
  • Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. 
  • Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database. 
  • Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. 
  • Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. 
  • Serum homocysteine and stroke in atrial fibrillation. 
  • Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. 
  • Sex Differences in Ablation Strategy, Lesion Sets, and Complications of Catheter Ablation for Atrial Fibrillation: An Analysis From the GWTG-AFIB Registry. 
  • Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT. 
  • Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry. 
  • Sex Differences in the Association Between Hypertension and Incident Atrial Fibrillation. 
  • Sex and Age Interactions and Differences in Outcomes After Intracerebral Hemorrhage. 
  • Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. 
  • Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. 
  • Shared medical appointments: Translating research into practice for patients treated with ablation therapy for atrial fibrillation. 
  • Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. 
  • Should His Bundle Pacing Be Preferred over Cardiac Resynchronization Therapy Following Atrioventricular Junction Ablation? 
  • Should patients on vitamin K antagonists be treated differently? 
  • Should rhythm control be preferred in younger atrial fibrillation patients? 
  • Should we just let the anticoagulation service do it? The conundrum of anticoagulation for atrial fibrillation. 
  • Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. 
  • Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. 
  • Simulation of Daily Snapshot Rhythm Monitoring to Identify Atrial Fibrillation in Continuously Monitored Patients with Stroke Risk Factors. 
  • Single-lead f-wave extraction using diffusion geometry. 
  • Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. 
  • Sinus Node Dysfunction and Atrial Fibrillation: A Reversible Phenomenon? 
  • Society of Cardiovascular Anesthesiologists/European Association of Cardiothoracic Anaesthetists Practice Advisory for the Management of Perioperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery. 
  • Society of Cardiovascular Anesthesiologists/European Association of Cardiothoracic Anaesthetists Practice Advisory for the Management of Perioperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery. 
  • Spontaneous occurrence of symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia in untreated patients. 
  • Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. 
  • Stability of rotors and focal sources for human atrial fibrillation: focal impulse and rotor mapping (FIRM) of AF sources and fibrillatory conduction. 
  • Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. 
  • Strategies to minimize the risk of esophageal injury during catheter ablation for atrial fibrillation. 
  • Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines - Heart Failure Program). 
  • Stroke Prediction in Atrial Fibrillation: Is it Black and White? 
  • Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2-VASc Scores: Findings From the ORBIT-AF I and II Registries. 
  • Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale. 
  • Stroke prevention guidelines. 
  • Stroke prevention in atrial fibrillation. 
  • Stroke prevention in atrial fibrillation: Closing the gap. 
  • Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe. 
  • Stroke prevention in patients with atrial fibrillation: disease burden and unmet medical needs. 
  • Stroke prevention: the emerging strategies. 
  • Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. 
  • Study of unipolar electrogram morphology in a computer model of atrial fibrillation. 
  • Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association. 
  • Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure). 
  • Suitability of the lumbar test dose for the thoracic epidural space. 
  • Surfing the biomarker tsunami at JACC: heart failure. 
  • Surgery for atrial fibrillation. 
  • Surgical Maze procedure as a treatment for atrial fibrillation: a meta-analysis of randomized controlled trials. 
  • Surgical ablation of atrial fibrillation trends and outcomes in North America. 
  • Surgical atrial fibrillation ablation: a review of contemporary techniques and energy sources. 
  • Symptom challenges after atrial fibrillation ablation. 
  • Systematic collection of patient-reported outcomes in atrial fibrillation: feasibility and initial results of the Utah mEVAL AF programme. 
  • TRM Forum on Computer Simulation and Experimental Assessment of Cardiac Function. 
  • Tackling Patient-Reported Outcomes in Atrial Fibrillation and Heart Failure: Identifying Disease-Specific Symptoms? 
  • Task Force 7: arrhythmias. 
  • Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. 
  • Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. 
  • Temporary autonomic modulation with botulinum toxin type A to reduce atrial fibrillation after cardiac surgery. 
  • Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. 
  • Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine. 
  • The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. 
  • The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. 
  • The Addition of Atrial Fibrillation to the Los Angeles Motor Scale May Improve Prediction of Large Vessel Occlusion. 
  • The Genetic Basis of Coronary Artery Disease and Atrial Fibrillation: A Search for Disease Mechanisms and Therapeutic Targets. 
  • The Incidence and Natural Progression of New-Onset Postoperative Atrial Fibrillation. 
  • The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. 
  • The Prevalence and Impact of Atrial Fibrillation on 1-Year Outcomes in Patients Undergoing Transcatheter Mitral Valve Repair: Results From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. 
  • The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review. 
  • The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2018 Update on Research: Outcomes Analysis, Quality Improvement, and Patient Safety. 
  • The association of left atrial low-voltage regions on electroanatomic mapping with low attenuation regions on cardiac computed tomography perfusion imaging in patients with atrial fibrillation. 
  • The association of patent foramen ovale and atrial fibrillation after coronary artery bypass graft surgery. 
  • The atrial FibriLlatiOn real World management registry in the Middle East and Africa: design and rationale. 
  • The burden of proof: The current state of atrial fibrillation prevention and treatment trials. 
  • The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. 
  • The comparative effects of drive and test stimulus intensity on myocardial excitability and vulnerability. 
  • The comparison of epicardial focused ultrasound circumferential pulmonary vein ablation and BOX ablation--results from experimental acute atrial fibrillation. 
  • The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring. 
  • The effects of atrial fibrillation on myocardial blood flow and energetics. 
  • The effects of atrial fibrillation on regional blood flow in the awake dog. 
  • The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. 
  • The impact of arrhythmias in acute heart failure. 
  • The impact of atrial fibrillation on outcomes in patients hospitalized with COVID-19. 
  • The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. 
  • The impact of postoperative atrial fibrillation on neurocognitive outcome after coronary artery bypass graft surgery. 
  • The importance of the design of observational studies in comparative effectiveness research: Lessons from the GARFIELD-AF and ORBIT-AF registries. 
  • The incidence and long-term clinical outcome of iatrogenic atrial septal defects secondary to transseptal catheterization with a 12F transseptal sheath. 
  • The increasing prevalence of atrial fibrillation among hemodialysis patients. 
  • The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. 
  • The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War? 
  • The left atrial appendage morphology is associated with embolic stroke subtypes using a simple classification system: A proof of concept study. 
  • The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. 
  • The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. 
  • The preexcitation syndromes. 
  • The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. 
  • The relation of quinidine-induced elevation of serum digoxin concentration to the conversion of atrial fibrillation-flutter: a pilot study. 
  • The reply. 
  • The role of atrial fibrillation catheter ablation in patients with heart failure. 
  • The role of posterior wall isolation in catheter ablation of persistent atrial fibrillation. 
  • The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. 
  • The significance of atrial fibrillation in patients aged ≥ 55 years undergoing abdominal surgery. 
  • The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. 
  • The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. 
  • Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF. 
  • Thromboembolism after WATCHMANTM in a clopidogrel non-responder: A case for concern? 
  • Thromboembolism after negative TEE. 
  • Thrombogenesis in atrial fibrillation contributing mechanisms and natural history. 
  • Thrombogenesis in atrial fibrillation: contributing mechanisms and natural history. 
  • Time in Therapeutic Range Significantly Impacts Survival and Adverse Events in Destination Therapy Patients. 
  • To be or not to be in normal sinus rhythm: what do we really know? 
  • To bridge or not to bridge: these are the questions. 
  • Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. 
  • Transesophageal assessment of left atrial thrombus using a 3.3-mm monoplane probe. 
  • Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. 
  • Transesophageal echocardiography and atrial fibrillation: added value or expensive toy? 
  • Transesophageal echocardiography before cardioversion. 
  • Transesophageal echocardiography versus oral anticoagulation before electrical cardioversion of atrial fibrillation: what about atrial clot size? 
  • Transesophageal echocardiography: useful tool or expensive toy? 
  • Transforming Atrial Fibrillation Research to Integrate Social Determinants of Health: A National Heart, Lung, and Blood Institute Workshop Report. 
  • Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation. 
  • Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. 
  • Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). 
  • Treatment of atrial fibrillation in East Asia: what is perception and what is reality? 
  • Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. 
  • Treatment of atrial fibrillation: is it as easy as A-B-C? 
  • Treatment of older patients with atrial fibrillation by morbidity burden. 
  • Treatment-Related Changes in Left Atrial Structure in Atrial Fibrillation: Findings From the CABANA Imaging Substudy. 
  • Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. 
  • Trends and Inpatient Outcomes of Primary Atrial Fibrillation Hospitalizations with Underlying Iron Deficiency Anemia: An Analysis of The National Inpatient Sample Database from 2004 -2018. 
  • Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020. 
  • Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. 
  • Triple Therapy for Atrial Fibrillation after PCI. 
  • Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. 
  • Troponin Improves the Yield of Transthoracic Echocardiography in Ischemic Stroke Patients of Determined Stroke Subtype. 
  • UNUSUAL NEUROLOGICAL AND CARDIOVASCULAR COMPLICATIONS OF RESPIRATORY FAILURE. 
  • Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician. 
  • Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib). 
  • Uninterrupted apixaban for atrial fibrillation ablation is a reasonable alternative, but what is the significance of silent cerebral infarctions? 
  • Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. 
  • Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. 
  • Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. 
  • Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. 
  • Use of Adjuncts Reduces Cardiopulmonary Bypass Time During Minimally Invasive Aortic Valve Replacement. 
  • Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. 
  • Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. 
  • Use of Direct Oral Anticoagulant and Outcomes in Patients With Atrial Fibrillation after Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry. 
  • Use of Direct Oral Anticoagulants in Special Populations. 
  • Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. 
  • Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation. 
  • Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. 
  • Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. 
  • Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. 
  • Use of left atrial appendage occlusion among older cardiac surgery patients with preoperative atrial fibrillation: a national cohort study. 
  • Usefulness of Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Myocardial Infarction. 
  • Usefulness of percutaneous balloon mitral commissurotomy in preventing the development of atrial fibrillation in patients with mitral stenosis. 
  • Using Data to Guide Anticoagulation in Patients With Atrial Fibrillation: Does the Analysis Fit the Question? 
  • Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. 
  • Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation. 
  • VVI pacing with normal QRS duration and ventricular function: MOST trial findings relevant to leadless pacemakers. 
  • Validation of an atrial fibrillation risk algorithm in whites and African Americans. 
  • Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT-AF II. 
  • Variation in Antithrombotic Therapy and Clinical Outcomes in Patients With Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. 
  • Variation in Warfarin Use at Hospital Discharge After Isolated Bioprosthetic Mitral Valve Replacement: An Analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database. 
  • Variation in left atrial transmural wall thickness at sites commonly targeted for ablation of atrial fibrillation. 
  • Vascular factors predict rate of progression in Alzheimer disease. 
  • Ventricular fibrillation in the Wolff-Parkinson-White syndrome. 
  • Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. 
  • Verapamil prolongs atrial fibrillation by evoking an intense sympathetic neurohumoral effect. 
  • Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. 
  • Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. 
  • Visualization of the esophagus during catheter ablation of atrial fibrillation. 
  • Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. 
  • Warfarin for Atrial Fibrillation Stroke Prophylaxis in Advanced Kidney Disease: If You Are Not Confused, You Are Not Thinking Clearly. 
  • Warfarin in vulnerable older adults with atrial fibrillation. 
  • Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. 
  • Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation. 
  • Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. 
  • Watchman device migration and embolization: A report from the NCDR LAAO Registry. 
  • Watchman implantation in a patient with left atrial appendage thrombus. 
  • Wavelet leader multifractal analysis of heart rate variability in atrial fibrillation. 
  • Weekend/holiday versus weekday hospital discharge and guideline adherence (from the American Heart Association's Get with the Guidelines--Coronary Artery Disease database). 
  • What to expect from net reclassification improvement with three categories. 
  • When Less Is Not More. 
  • When Low-Risk Atrial Fibrillation Is Not So Low Risk: Beast of Burden. 
  • When the body and appendage of the left atrium disagree: "Focal" atrial fibrillation-implications for atrial thrombus formation and risk of thromboembolism. 
  • Zones of atrial vulnerability. Relationships to basic cycle length. 
  • [Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments]. 
  • [Brazilian guidelines on platelet antiaggregants and anticoagulants in cardiology]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Allen LaPointe, Nancy Marie, Adjunct Associate Professor in the Department of Medicine, Medicine, Cardiology
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Friedman, Daniel, Assistant Professor of Medicine, Medicine, Cardiology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Starmer, Charles Franklin, Professor Emeritus of Computer Science, Computer Science
  • Williams Jr., Judson Blount, Assistant Consulting Professor in the Department of Surgery, Surgery, Cardiovascular and Thoracic Surgery